Paushak Q2 FY27: standalone PAT +57% YoY to ₹13.5 Cr, OPM up 430bps; QoQ softer on tax
PAT +56.86% YoY · revenue +51.96% · margins expanding
₹89.32 Cr
+51.96% YoY
₹13.51 Cr
+56.86% YoY
14.79%
+0.4pp YoY
₹5.48
Paushak's standalone revenue from operations came in at ₹89.32 Cr, up 51.9% YoY (₹58.78 Cr) and 6.9% QoQ (₹83.55 Cr), with PAT of ₹13.51 Cr, up 56.9% YoY (₹8.61 Cr) but down 10.6% QoQ (₹15.10 Cr). Basic EPS was ₹5.48 against a restated ₹3.49 a year ago and ₹6.13 last quarter. Only a standalone statement was filed — the company has one reportable segment and no consolidated results.
Q2 FY-2027 vs prior quarters
Operating margin (EBITDA on revenue from operations) expanded 430bps YoY to 29.5% from 25.2%, pointing to operating leverage on higher volumes, though it eased 119bps from Q1FY27's 30.7%. Net margin was roughly flat YoY (14.8% vs 14.4%) but down from 17.4% last quarter. The sequential profit decline was tax-driven rather than operational: PBT was nearly flat QoQ (₹18.60 Cr vs ₹19.02 Cr, -2.2%), but the effective tax rate jumped to 27.4% from 20.6% in Q1FY27 (current tax ₹2.74 Cr + deferred tax ₹2.35 Cr, versus ₹2.49 Cr + ₹1.42 Cr), pulling PAT down 10.6% QoQ. Finance costs also stepped up to ₹1.35 Cr from a near-nil ₹0.04 Cr a year earlier, and depreciation nearly doubled YoY (₹8.44 Cr vs ₹4.47 Cr) — both consistent with the FY26 capex/borrowing build (₹35 Cr of non-current borrowing proceeds were raised in H1FY26 per the cash-flow statement, with ₹7.5 Cr repaid in the current half).
The stock went into the print at ₹826.35, up 17.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Paid-up equity capital ₹12.33 Cr vs ₹3.08 Cr YoY on a bonus/stock-split action — EPS comparisons must use the restated ₹3.49 base, not unadjusted prior figures
No analyst coverage exists for this stock (TipRanks shows zero covering analysts), so there is no street estimate to grade this print against, and management has issued no formal guidance on record — this result cannot be benchmarked to either. No management press release accompanied the filing for additional commentary. The quarter's corporate calendar — the October 16 board meeting, the October 1 trading-window closure, and the July 30 AGM — was procedural, with no capacity, deal, or management-change events feeding into the numbers.
W1
Effective tax rate: whether it reverts toward Q1FY27's ~20.6% or persists near 27.4%, which directly sets next quarter's PAT growth
W2
OPM trajectory: whether margin holds in the 29-31% band seen through H1FY27 or slips further from the 30.7% Q1 peak
W3
Finance cost run-rate: whether it stays near ₹1.3-1.4 Cr/quarter as non-current borrowings (₹52.5 Cr as of Sep'26, down from ₹60 Cr at FY26-end) continue to amortise
Standalone-only filing (single entity, one reportable segment — speciality chemicals); no consolidated statement. Our prior-period record's year-ago EPS (₹27.94) predates the FY26 bonus/stock-split (paid-up capital ₹3.08 Cr → ₹12.33 Cr); this filing's own restated comparative of ₹3.49 is used for YoY. No exceptional items disclosed.
Informational and educational content only. Not investment advice.